BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 32487642)

  • 1. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Moon SM; Kim JH; Kim SK; Kim S; Kwon HJ; Bae JS; Lee S; Lee HS; Choi MY; Jeon BH; Jeong BH; Lee K; Kim HK; Kim J; Um SW
    Anticancer Res; 2020 Jun; 40(6):3435-3444. PubMed ID: 32487642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
    Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
    Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.
    Freidin MB; Freydina DV; Leung M; Montero Fernandez A; Nicholson AG; Lim E
    Clin Chem; 2015 Oct; 61(10):1299-304. PubMed ID: 26272233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer.
    Li Y; Tian X; Gao L; Jiang X; Fu R; Zhang T; Ren T; Hu P; Wu Y; Zhao P; Yang D
    Cancer Med; 2019 Jul; 8(8):3782-3792. PubMed ID: 31132233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
    Rossi G; Mu Z; Rademaker AW; Austin LK; Strickland KS; Costa RLB; Nagy RJ; Zagonel V; Taxter TJ; Behdad A; Wehbe FH; Platanias LC; Gradishar WJ; Cristofanilli M
    Clin Cancer Res; 2018 Feb; 24(3):560-568. PubMed ID: 29180605
    [No Abstract]   [Full Text] [Related]  

  • 12. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy.
    Muhanna N; Eu D; Chan HHL; Douglas C; Townson JL; Di Grappa MA; Mohamadi RM; Kelley SO; Bratman SV; Irish JC
    BMC Cancer; 2021 Oct; 21(1):1075. PubMed ID: 34600526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.
    Förnvik D; Aaltonen KE; Chen Y; George AM; Brueffer C; Rigo R; Loman N; Saal LH; Rydén L
    Breast Cancer Res Treat; 2019 Sep; 177(2):447-455. PubMed ID: 31236809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs.
    Xie J; Hu B; Gong Y; He S; Lin J; Huang Q; Cheng J
    J Transl Med; 2023 Dec; 21(1):873. PubMed ID: 38041139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.